The Scientist

» biotech and microbiology

Most Recent

image: Another CRISPR Biotech Goes Public

Another CRISPR Biotech Goes Public

By | September 12, 2016

CRISPR Therapeutics, the company started by a pioneer of the gene editing technology, plans to raise $90 million from an initial public offering.

0 Comments

image: Neonatal Gut Bacteria Might Promote Asthma

Neonatal Gut Bacteria Might Promote Asthma

By | September 12, 2016

Byproducts of gut microbes in some 1-month–old babies trigger inflammation that is linked to later asthma development, researchers find.

1 Comment

image: Giant Petri Dish Displays Evolution in Space and Time

Giant Petri Dish Displays Evolution in Space and Time

By | September 8, 2016

As E. coli bacteria spread over increasingly concentrated antibiotics, researchers discover novel evolutionary pathways that confer resistance.

7 Comments

image: Promoting Protein Partnerships

Promoting Protein Partnerships

By | September 1, 2016

Scientists generate new protein-protein interactions at an impressive PACE.

0 Comments

image: Protein or Perish

Protein or Perish

By | September 1, 2016

A bacteriophage must evolve certain variants of a protein or die.

0 Comments

image: That Other CRISPR Patent Dispute

That Other CRISPR Patent Dispute

By | August 31, 2016

The Broad Institute and Rockefeller University disagree over which scientists should be named as inventors on certain patents involving the gene-editing technology.

1 Comment

A patent dispute over CRISPR highlights the need for scientists to agree on IP ownership early.

0 Comments

image: Antibiotic Resistance Reaches Brazil

Antibiotic Resistance Reaches Brazil

By | August 8, 2016

Scientists detect a colistin-resistance gene in a clinical sample.

0 Comments

image: Theranos CEO Presents New Device

Theranos CEO Presents New Device

By | August 2, 2016

The troubled firm’s medical conference appearance didn’t deliver the evidence many hoped for.

0 Comments

image: Fecal Transplant Pill Fails Trial

Fecal Transplant Pill Fails Trial

By | August 1, 2016

Seres Therapeutics’s microbiome-targeting therapy for recurrent Clostridium difficile infection fails a Phase 2 clinical trial.

2 Comments

Popular Now

  1. A Newly Identified Species Represents Its Own Eukaryotic Lineage
  2. Telomere Length and Childhood Stress Don’t Always Correlate
  3. Optogenetic Therapies Move Closer to Clinical Use
  4. Research Links Gut Health to Neurodegeneration
    The Nutshell Research Links Gut Health to Neurodegeneration

    Rodent studies presented at the Society for Neuroscience meeting this week tie pathologies in the gastrointestinal tract or microbiome composition with Parkinson’s and Alzheimer’s diseases.

RayBiotech